<DOC>
	<DOCNO>NCT01497561</DOCNO>
	<brief_summary>This trial conduct Europe . The aim trial investigate pharmacodynamics pharmacokinetics single dos insulin detemir insulin NPH subject type 2 diabetes .</brief_summary>
	<brief_title>Pharmacodynamics Pharmacokinetics Insulin Detemir Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Isophane insulin , beef</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Detemir</mesh_term>
	<mesh_term>Isophane Insulin , Human</mesh_term>
	<mesh_term>Insulin , Isophane</mesh_term>
	<criteria>Type 2 diabetes Subjects treat insulin minimum 3 month Duration diabetes least 12 month Body Mass Index ( BMI ) 30 kg/m^2 HbA1c maximum 10 % base analysis central laboratory Current treatment insulin 1.2 U/kg/day Current treatment insulin glargine Current treatment drug know interfere glucose metabolism Current treatment oral antidiabetic drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>